🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "huge turning point" in the battle against drug-resistant strains of the infection, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are on the rise globally, with data suggesting more than 82 million instances annually. Especially elevated rates are observed in the African continent and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune advancement in the face of rising global incidence, increasing antimicrobial resistance and the highly restricted treatment choices currently available.”

Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has listed it as a "critical concern". A tracking program found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Secure Authorization

One new antibiotic, marketed under the name Nuzolvence, was cleared by the American regulatory agency in recent days for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers hope that focused deployment of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This approval signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Testing Data and Global Access

As per data released by a prominent scientific publication, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This puts it on an similar efficacy with the existing first-line therapy, which uses two antibiotics. The research involved over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the authority to license and sell the drug in many low-income and middle-income countries.

Medical professionals treating patients have shared optimism. The availability of a easy-to-administer therapy of this kind is described as a "game-changer" for managing the epidemic. This is deemed essential to lessen the impact of the infection for individuals and to stop the proliferation of untreatable gonorrhoea globally.